August 4, 2014
The Pharmaceuticals and Medical Devices Agency’s (PMDA) new five-year plan for FY2014-FY2018 sets targets for overall review time for partial modifications of approval for generics and long-listed products, or off-patent original drugs. The PMDA aims to reduce review time to...read more